Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody.

As the coronavirus disease 2019 (COVID-19) pandemic continues, there is a strong need for highly potent monoclonal antibodies (mAbs) that are resistant against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VoCs). Here, we evaluate the potency of the previously described mAb J08 against these variants using cell-based ...
assays and delve into the molecular details of the binding interaction using cryoelectron microscopy (cryo-EM) and X-ray crystallography. We show that mAb J08 has low nanomolar affinity against most VoCs and binds high on the receptor binding domain (RBD) ridge, away from many VoC mutations. These findings further validate the phase II/III human clinical trial underway using mAb J08 as a monoclonal therapy.
Mesh Terms:
Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, Antibody Affinity, COVID-19, Humans, Neutralization Tests, SARS-CoV-2
Proc Natl Acad Sci U S A
Date: Dec. 17, 2021
Download Curated Data For This Publication
231777
Switch View:
  • Interactions 2